Search Cancer Clinical Trials

Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
7 results
  • Breast Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Sarcoma, Thyroid Cancer

23-301          Phase I

A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants with Advanced Solid Tumors

  • Ovarian Cancer, Melanoma, Lung Cancer, Kidney Cancer, Head and Neck Cancer, Bladder Cancer, Breast Cancer

21-329          Phase II

A Phase 1a Open-Label, Dose-Escalation, and a Phase 2 Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of ST-067 Administered Subcutaneously as Monotherapy in Patients with Relapsed or Refractory Solid Tumors

  • Breast Cancer, Prostate Cancer, Bladder Cancer, Sarcoma, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Gastric (Stomach) Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer

23-392          Phase I

A Phase 1a/1b, Dose-Escalation/Dose-Expansion study of NPX267 in Subjects with Solid Tumors Known to Express HHLA-2

  • Ovarian Cancer, Rectal Cancer, Thymoma, Colorectal Cancer, Gastric (Stomach) Cancer, Head and Neck Cancer, Esophageal Cancer, Melanoma, Lung Cancer, Kidney Cancer

23-423          Phase I

A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination with Pembrolizumab in Patients with Select Advanced Cancers

  • Lung Cancer, Kidney Cancer, Metastatic/Advanced Cancer, Head and Neck Cancer, Melanoma

22-614          Phase I

An Open-Label Phase 1a/1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination with Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

  • Kidney Cancer, Ovarian Cancer, Melanoma

22-062          Phase II

IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 ß/¿ Alone or in Combination with Pembrolizumab or Standard of Care Chemotherapy in Participants Aged 18 Years or Older with Locally Advanced or Metastatic Solid Tumor Malignancies

  • Kidney Cancer

22-488          Phase II

RANDOMIZED PHASE II STEREOTACTIC ABLATIVE RADIATION THERAPY (SABR) FOR METASTATIC UNRESECTED RENAL CELL CARCINOMA (RCC) RECEIVING IMMUNOTHERAPY (SAMURAI)

Showing 1 - 10 of 7 results